Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VC005 in healthy subjects and mild to moderate atopic dermatitis
NCT06009094Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VC-005 in atopic dermatitis (AD) (5 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoint: Peak Plasma Concentration at Day 31. Started Jul 2023; status: completed.
02
Drugs
VC-005
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06009094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009094.